Significados de pralatrexate em inglês

This favorable survival result was seen in most prespecified subgroups for pralatrexate.

These results indicate that pralatrexate is generally well tolerated and effective in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.

A trend toward improvement in OS favoring pralatrexate was observed with an HR of 0.84 (95% confidence interval: 0.61-1.14) in the intent-to-treat population.

Pralatrexate is a novel antifolate approved in the USA for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Pralatrexate, which has already received FDA's orphan drug status to treat T-cell lymphoma, is being tested as a treatment for large B-cell lymphoma.